Slone Partners Recruits Chief Legal Officer for InterVenn Biosciences

May 20, 2021 – Over the past few months, numerous healthcare and life sciences organizations have turned to executive search firms to find new leaders. In the era of COVID-19, the sector has been a burgeoning area for executive search firms to ply their trade. Recently, life sciences-focused search firm Slone Partners placed Stephana Patton as chief legal officer at InterVenn Biosciences. “Dr. Patton is an extraordinarily talented and experienced legal mind with a track record of success wherever she’s been,” said Tara Kochis-Stach, president of Slone Partners. “She brings terrific insight and intellect to the InterVenn executive team.”

Dr. Patton has more than 20 years of legal experience. She most recently served as general counsel, corporate secretary and chief compliance officer at Eiger Biopharmaceuticals, where she was responsible for all legal and compliance matters. Previously, Dr. Patton served as general counsel, corporate secretary and chief compliance officer at BioTime Inc., and as vice president, general counsel and commercial compliance officer at BioDelivery Sciences International. She began her pharmaceutical industry career at Salix Pharmaceuticals, where she was VP of intellectual property and licensing until the company was acquired by Valeant Inc. in 2015.

“We are thrilled to welcome Stephana to our team,” said Aldo Carrascoso, CEO at InterVenn. “Her leadership and experience will provide strength to the leadership team and will greatly benefit InterVenn this year and in the years to come.”

Based in South San Francisco, InterVenn Biosciences utilizes a proprietary glycoproteomic biomarker interrogation platform using AI and mass spectrometry for next-gen precision medicine. The company is working to find new solutions in ovarian, pancreatic, liver, prostate and kidney cancer, together with applications from the Vista suite of solutions for treatment and monitoring, immune profiling, patient stratification and disease progression.

Nationally Recognized

Slone Partners is a nationally recognized senior-level recruitment provider that specializes in delivering executive, management and leadership talent for the diagnostic, biopharmaceutical, healthcare information technology and laboratory testing industries. The firm has offices in Boston, New York, Washington, D.C. and San Francisco. Recently, the firm was included among Hunt Scanlon Media’s “Top 50 Healthcare & Life Sciences Search Firms.”

Slone Partners Recruits CEO for Mesa Biotech
The race is on to find a vaccine for COVID-19 – and along with it the pace is picking up to find top leadership talent at many of the nation’s leading life sciences, medical diagnostics and biotech companies. Here’s one of the latest searches just successfully completed.

Ms. Kochis-Stach joined Slone Partners in 2004, bringing to the firm over a decade of healthcare experience. Her past sales career with industry leaders such as VERSYSS, American Medical Laboratories and Quest Diagnostics covered a wide variety of healthcare segments, including information technology, medical records, and the diagnostic and laboratory testing industry. Prior to healthcare, Ms. Kochis-Stach recruited executive and management talent in the banking and finance sector.

Recent Placement

The firm recently placed Mike Spigarelli as chief medical officer of Lumen Bioscience in Seattle. “As an extremely skilled industry leader with three decades of medical, pharmaceutical and academic experience, Mike Spigarelli has a thorough understanding of clinical affairs, drug development and regulatory strategy,” said Ms. Kochis-Stach, of Slone Partners. “He will be a tremendously valuable addition to the Lumen Bio executive team at a time when the company is advancing a number of exciting new investigational biologic drugs.”

Related: Slone Partners Places Chief Medical Officer at Goldfinch Bio

Contributed by Scott A. Scanlon, Editor-in-Chief; Dale M. Zupsansky, Managing Editor; and Stephen Sawicki, Managing Editor – Hunt Scanlon Media

Share This Article


Notify of
Inline Feedbacks
View all comments